{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:24:41Z","timestamp":1770492281824,"version":"3.49.0"},"reference-count":24,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,13]]},"DOI":"10.31744\/einstein_journal\/2020ao4995","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T19:47:53Z","timestamp":1581623273000},"source":"Crossref","is-referenced-by-count":11,"title":["Antiretroviral drug use by individuals living with HIV\/AIDS and compliance with the Clinical Protocol and Therapy Guidelines"],"prefix":"10.31744","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7409-3356","authenticated-orcid":false,"given":"Lucas Eduardo Fedaracz","family":"Brojan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4241-2850","authenticated-orcid":false,"given":"Leticia Mara","family":"Marca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8210-1600","authenticated-orcid":false,"given":"Frederico Alves","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7132-0939","authenticated-orcid":false,"given":"Yanna Dantas","family":"Rattmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16942","reference":[{"issue":"13","key":"key20200213144746_B1","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1097\/QAD.0b013e328362ba67","article-title":"The burden of HIV: insights from the Global Burden of Disease Study 2010","volume":"27","author":"Ortblad","year":"2013","unstructured":"1. Ortblad KF, Lozano R, Murray CJ. The burden of HIV: insights from the Global Burden of Disease Study 2010. AIDS. 2013;27(13):2003-17.","journal-title":"AIDS"},{"key":"key20200213144746_B2","author":"Brasil","year":"1996","unstructured":"2. Brasil. Lei n. 9313 de 13 de novembro de 1996. Disp\u00f5e sobre a distribui\u00e7\u00e3o gratuita de medicamentos aos portadores do HIV e doentes de AIDS [Internet]. Presid\u00eancia da Rep\u00fablica do Brasil. Bras\u00edlia (DF); 1996 Nov 14 [citado 2019 Jul 17]. Dispon\u00edvel em: http:\/\/www.planalto.gov.br\/ccivil_03\/leis\/l9313.htm","journal-title":"Lei n. 9313 de 13 de novembro de 1996. Disp\u00f5e sobre a distribui\u00e7\u00e3o gratuita de medicamentos aos portadores do HIV e doentes de AIDS"},{"key":"key20200213144746_B3","author":"Brasil","year":"2018","unstructured":"3. Brasil. Minist\u00e9rio da Sa\u00fade. Boletim Epidemiol\u00f3gico HIV\/AIDS 2018 [Internet]. Bras\u00edlia (DF); 2018 [citado 2019 Jul 17]. Dispon\u00edvel em: http:\/\/www.aids.gov.br\/pt-br\/pub\/2018\/boletim-epidemiologico-hivaids-2018","journal-title":"Boletim Epidemiol\u00f3gico HIV\/AIDS 2018"},{"key":"key20200213144746_B4","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1590\/S1413-81232010000900028","article-title":"Dilemas da pol\u00edtica de distribui\u00e7\u00e3o de medicamentos antirretrovirais no Brasil","volume":"15","author":"Lago","year":"2010","unstructured":"4. Lago RF, Costa NR. Dilemas da pol\u00edtica de distribui\u00e7\u00e3o de medicamentos antirretrovirais no Brasil. Ci\u00eanc Sa\u00fade Colet. 2010;15(Supl 3):3529-40.","journal-title":"Ci\u00eanc Sa\u00fade Colet"},{"issue":"3","key":"key20200213144746_B5","first-page":"1987","article-title":"Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review)","volume":"19","author":"Venanzi Rullo","year":"2019","unstructured":"5. Venanzi Rullo E, Ceccarelli M, Condorelli F, Facciol\u00e0 A, Visalli G, D\u2019Aleo F, et al. Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review). Mol Med Rep. 2019;19(3):1987-95. Review.","journal-title":"Mol Med Rep"},{"key":"key20200213144746_B6","author":"Brasil","year":"2017","unstructured":"6. Brasil. Minist\u00e9rio da Sa\u00fade. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para o Manejo da Infec\u00e7\u00e3o pelo HIV em Adultos [Internet]. Bras\u00edlia (DF); 2017 [citado 2019 Jul 18]. Dispon\u00edvel em: http:\/\/www.aids.gov.br\/pt-br\/pub\/2013\/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos","journal-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para o Manejo da Infec\u00e7\u00e3o pelo HIV em Adultos"},{"issue":"4","key":"key20200213144746_B7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.medmal.2018.10.005","article-title":"Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France","volume":"49","author":"Pugliese","year":"2019","unstructured":"7. Pugliese P, Joly V, Valentin MA, Cotte L, Huleux T, Allavena C, Reynes J, Poizot-Martin I, Bani-Sadr F, Cuzin L; Dat\u2019AIDS group. Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France. Med Mal Infect. 2019;49(4):264-9.","journal-title":"Med Mal Infect"},{"issue":"3","key":"key20200213144746_B8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.18433\/J31G7R","article-title":"Evaluation of the efficacy and safety of changes in antiretroviral regimens for HIV-infected patients","volume":"17","author":"Tanaka","year":"2014","unstructured":"8. Tanaka H, Wada T, Takayama Y, Matsumoto K, Atsuda K, Satoh M. Evaluation of the efficacy and safety of changes in antiretroviral regimens for HIV-infected patients. J Pharm Pharm Sci. 2014;17(3):316-23.","journal-title":"J Pharm Pharm Sci"},{"issue":"3","key":"key20200213144746_B9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1124\/pr.117.013706","article-title":"Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs","volume":"70","author":"Dalwadi","year":"2018","unstructured":"9. Dalwadi DA, Ozuna L, Harvey BH, Viljoen M, Schetz JA. Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs. Pharmacol Rev. 2018;70(3):684-711. Review.","journal-title":"Pharmacol Rev"},{"key":"key20200213144746_B10","author":"Brasil","year":"2017","unstructured":"10. Brasil. Minist\u00e9rio da Sa\u00fade. Departamento de Vigil\u00e2ncia, Preven\u00e7\u00e3o e Controle de IST, do HIV\/AIDS e das Hepatites Virais. Nota Informativa n. 007\/2017 [Internet]. Bras\u00edlia (DF); 2017 [citado 2019 Jul 18]. Dispon\u00edvel em: http:\/\/www.aids.gov.br\/pt-br\/legislacao\/nota-informativa-no-0072017-ddahv-svs-ms","journal-title":"Nota Informativa n. 007\/2017"},{"issue":"10","key":"key20200213144746_B11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162775","article-title":"Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors as Initial Antiretroviral Therapy for People with HIV: A Systematic Review","volume":"11","author":"Rutherford","year":"2016","unstructured":"11. Rutherford GW, Horvath H. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors as Initial Antiretroviral Therapy for People with HIV: A Systematic Review. PLoS One. 2016;11(10):e0162775. Review.","journal-title":"PLoS One"},{"key":"key20200213144746_B12","author":"Brasil","year":"2017","unstructured":"12. Brasil. Minist\u00e9rio da Sa\u00fade. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para a Preven\u00e7\u00e3o da Transmiss\u00e3o Vertical de HIV, S\u00edfilis e Hepatites Virais [Internet]. Bras\u00edlia (DF); 2017 [citado 2019 Jul 18]. Dispon\u00edvel em: http:\/\/www.aids.gov.br\/pt-br\/pub\/2015\/protocolo-clinico-e-diretrizes-terapeuticas-para-prevencao-da-transmissao-vertical-de-hiv","journal-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para a Preven\u00e7\u00e3o da Transmiss\u00e3o Vertical de HIV, S\u00edfilis e Hepatites Virais"},{"issue":"3","key":"key20200213144746_B13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","unstructured":"13. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo JM; VIKING-3 Study Group. Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354-62.","journal-title":"J Infect Dis"},{"issue":"4","key":"key20200213144746_B14","first-page":"205","article-title":"Boosted protease inhibitor-based or nonucleoside reverse transcriptase- based HAART: is there a best choice for antirretroviral- naive HIV-1 infected patients?","volume":"10","author":"Cuzin","year":"2008","unstructured":"14. Cuzin L, Allavena C, Morlat P, Dellamonica P. Boosted protease inhibitor-based or nonucleoside reverse transcriptase- based HAART: is there a best choice for antirretroviral- naive HIV-1 infected patients? AIDS Rev. 2008;10(4):205-11. Review.","journal-title":"AIDS Rev"},{"issue":"2","key":"key20200213144746_B15","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(14)00061-7","article-title":"Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis","volume":"2","author":"Boyd","year":"2015","unstructured":"15. Boyd MA, Moore CL, Molina JM, Wood R, Madero JS, Wolff M, Ruxrungtham K, Losso M, Renjifo B, Teppler H, Kelleher AD, Amin J, Emery S, Cooper DA; SECOND-LINE study group. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Lancet HIV. 2015;2(2):e42-51.","journal-title":"Lancet HIV"},{"key":"key20200213144746_B16","author":"Brasil","year":"2008","unstructured":"16. Brasil. Minist\u00e9rio da Sa\u00fade. Recomenda\u00e7\u00f5es para terapia antirretroviral em adultos infectados pelo HIV [Internet]. Bras\u00edlia; 2008 [citado 2019 Jul 18]. http:\/\/www.aids.gov.br\/pt-br\/pub\/2007\/recomendacoes-para-terapia-antirretroviral-em-adultos-infectados-pelo-hiv-2008","journal-title":"Recomenda\u00e7\u00f5es para terapia antirretroviral em adultos infectados pelo HIV"},{"issue":"3","key":"key20200213144746_B17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3851\/IMP1539","article-title":"Clonal resistance analyses of HIV-1 after failure of therapy with didanosine, lamivudine, and tenofovir","volume":"15","author":"Barnas","year":"2010","unstructured":"17. Barnas D, Koontz D, Bazmi H, Bixby C, Jemsek J, Mellors JW. Clonal resistance analyses of HIV-1 after failure of therapy with didanosine, lamivudine, and tenofovir. Antivir Ther. 2010;15(3):437-41.","journal-title":"Antivir Ther"},{"issue":"10","key":"key20200213144746_B18","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJMc070207","article-title":"A comparison of three initial antiretroviral AIDS regimens","volume":"357","author":"Ribaudo","year":"2007","unstructured":"18. Ribaudo HJ, Kuritzkes DR, Gulick RM. A comparison of three initial antiretroviral AIDS regimens. N Engl J Med. 2007;357(10):1056-7.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20200213144746_B19","first-page":"38","article-title":"Updated classification for medication errors by the Ruiz-Jarabo 2000 Group","volume":"32","author":"Otero L\u00f3pez","year":"2008","unstructured":"19. Otero L\u00f3pez MJ, Casta\u00f1o Rodr\u00edguez B, P\u00e9rez Encinas M, Codina Jan\u00e9 C, T\u00e1mes Alonso MJ, S\u00e1nchez Mu\u00f1oz T; Ruiz-Jarabo 2000 Work Group. [Updated classification for medication errors by the Ruiz-Jarabo 2000 Group]. Farm Hosp. 2008;32(1):38-52. Spanish.","journal-title":"Farm Hosp"},{"issue":"1","key":"key20200213144746_B20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-0038-1677009","article-title":"Reduced Verification Of Medication Alerts Increases Prescribing Errors","volume":"10","author":"Lyell","year":"2019","unstructured":"20. Lyell D, Magrabi F, Coiera E. Reduced Verification Of Medication Alerts Increases Prescribing Errors. Appl Clin Inform. 2019;10(1):66-76.","journal-title":"Appl Clin Inform"},{"issue":"1","key":"key20200213144746_B21","first-page":"59","article-title":"Patching a leaky pipe: the cascade of HIV care","volume":"8","author":"Kilmarx","year":"2013","unstructured":"21. Kilmarx PH, Mutasa-Apollo T. Patching a leaky pipe: the cascade of HIV care. Curr Opin HIV AIDS. 2013;8(1):59-64. Review.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"key20200213144746_B22","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-018-6325-5","article-title":"HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme","volume":"19","author":"Dharan","year":"2019","unstructured":"22. Dharan NJ, Radovich T, Che S, Petoumenos K, Juneja P, Law M, et al. HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme. BMC Public Health. 2019;19(1):13.","journal-title":"BMC Public Health"},{"issue":"9","key":"key20200213144746_B23","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1590\/S1413-81232012000900019","article-title":"Dispensa\u00e7\u00e3o de medicamentos do componente especializado em polos no Estado do Rio de Janeiro","volume":"17","author":"Lima-Dellamora","year":"2012","unstructured":"23. Lima-Dellamora EC, Caetano R, Osorio-de-Castro CG. Dispensa\u00e7\u00e3o de medicamentos do componente especializado em polos no Estado do Rio de Janeiro. Ci\u00eanc Sa\u00fade Colet. 2012;17(9):2387-96.","journal-title":"Ci\u00eanc Sa\u00fade Colet"},{"issue":"12","key":"key20200213144746_B24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","unstructured":"24. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, Burchell AN, Cohen M, Gebo KA, Gill MJ, Justice A, Kirk G, Klein MB, Korthuis PT, Martin J, Napravnik S, Rourke SB, Sterling TR, Silverberg MJ, Deeks S, Jacobson LP, Bosch RJ, Kitahata MM, Goedert JJ, Moore R, Gange SJ; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355.","journal-title":"PLoS One"}],"container-title":["Einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T19:48:12Z","timestamp":1581623292000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/antiretroviral-drug-use-by-individuals-living-with-hiv-aids-and-compliance-with-the-clinical-protocol-and-therapy-guidelines\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":24,"alternative-id":["10.31744\/einstein_journal\/2020AO4995"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2020ao4995","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"article-number":"eAO4995"}}